|
    PFE U.S.: NYSE
    PFEUS
    Open
    Back To Top
    Last Updated: May 6, 2021 9:43 a.m. EDT Real time quote

    $ 38.52

    -1.06 -2.68%
    Previous Close
    $39.97
    Advanced Charting
    • $
    • %
    • Vol
    Volume: 3.17M 65 Day Avg: 29.68M
    11% vs Avg
    37.96 Day Range 39.58
    29.94 52 Week Range 43.08

    Your Watchlists

    Customize eLesor

    Have Watchlists? Log in to see them here or sign up to get started.

    Symbol
    Company
    Price
    Chg/Chg %
    No Items in Watchlist

    There are currently no items in this Watchlist.

    Uh oh

    Something went wrong while loading Watchlist.

    Recently Viewed Tickers

    No Recent Tickers

    Visit a quote page and your recently viewed tickers will be displayed here.

    PFE Overview

    Performance

    5 Day
    • -0.21%
    1 Month
    • 7.12%
    3 Month
    • 10.40%
    YTD
    • 4.65%
    1 Year
    • 10.02%

    Analyst Ratings

    • Sell
    • Under
    • Hold
    • Over
    • Buy
    Number of Ratings 21 Full Ratings

    Recent News

    • eLesor
    • Dow Jones
    Read full story

    Moderna Reports First Profitable Quarter. Patent Worries Are Slamming the Stock.

    Read full story

    Dow inches higher but broader market wobbles as jobless claims carve out fresh COVID low

    Read full story

    Pfizer’s next play: A vaccine maker and pandemic ‘partner’ to governments

    Pfizer downgraded to neutral from buy at Mizuho

    Moderna says its COVID-19 vaccine has a 96% efficacy rate in teens who have received one shot

    Regeneron Earnings Lift Stock. Here’s Why.

    Pfizer and BioNTech to supply IOC with COVID-19 vaccines for Olympic athletes

    Vaccine makers lower after U.S. says it supports IP waivers

    Read full story

    Pfizer Inc. stock rises Wednesday, still underperforms market

    Read full story

    Dow books 22nd record close of 2021, but tech stocks slip for 4th day

    Biden administration backs waiving IP protections for COVID vaccines

    Read full story

    U.S. Birthrate Dropped 4% in 2020, Hurt By the Pandemic

    Read full story

    Pfizer Will Meet Growth Goals Even Without Vaccine Sales, CFO Says

    Canada authorizes Pfizer's COVID-19 vaccine for kids between the ages of 12 and 15 years old

    Read full story

    Moderna Reports Earnings on Thursday. Here’s What to Expect.

    Read full story

    CVS banks on future gains from pediatric vaccines as hesitant adults drive recent COVID vaccination decline

    Read full story

    Pfizer Inc. stock underperforms Tuesday when compared to competitors despite daily gains

    Read full story

    What happened in the stock market today? Tech sees worst day since March, Dow ekes out gain

    Read full story

    EU regulator starts ‘rolling review’ of China’s Sinovac COVID-19 vaccine

    Read full story

    Pfizer’s Vaccine Drove a Big Earnings Beat. What It Means for the Stock.

    • Other News
    • Press Releases

    Thursday’s Top Analysts Upgrades and Downgrades: Apple, Darden Restaurants, Peloton, Pfizer, Pioneer Natural Resources and More

    on 247WallSt.com

    Is It Too Late to Buy Johnson & Johnson Stock?

    on Motley Fool

    Vaxart Has 3 Advantages Over Pfizer and Moderna

    on Motley Fool

    Pfizer Stock Looks Healthy At Current Levels

    on TipRanks.com

    Biden Administration Supports Patent Waivers for Coronavirus Vaccine

    on Motley Fool

    Why BioNTech Stock Is Jumping Again Today

    on Motley Fool

    Why Ocugen Stock Continues to Be a Great Short Opportunity

    on InvestorPlace.com

    Deciphera (DCPH) Q1 Loss Narrower Than Expected, Revenues Beat

    on Zacks.com

    Has Pfizer (PFE) Outpaced Other Medical Stocks This Year?

    on Zacks.com

    Should Pfizer and Moderna Be Worried About This New COVID Vaccine Study?

    on Motley Fool

    Can This News Push Ocugen Ahead of Pfizer and Moderna?

    on Motley Fool

    Should You Buy Novavax Before Its Earnings Report?

    on Motley Fool

    Pfizer (PFE) Q1 2021 Earnings Call Transcript

    on Motley Fool

    Pfizer (PFE) Gains As Market Dips: What You Should Know

    on Zacks.com

    Pfizer (PFE) Q1 Earnings Beat, COVID-19 Vaccine Boosts Sales

    on Zacks.com

    Why BioNTech Stock Is Sinking Today

    on Motley Fool

    Q1 Earnings Season Maintains its Momentum

    on Zacks.com

    Pfizer Knocks It Out of the Park With Its Q1 Results

    on Motley Fool

    What Will the Stock Market Do Today? 3 Big Stories to Watch.

    on InvestorPlace.com

    Pfizer Reports Better-Than-Expected 1Q Results, Lifts COVID-19 Vaccine Sales Outlook

    on TipRanks.com

    Pfizer Inc.

    Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

    Competitors

    Name Chg % Market Cap
    Eli Lilly & Co. -1.30% $184.91B
    AstraZeneca PLC ADR -0.84% $140.13B
    Johnson & Johnson -0.18% $439.96B
    Bristol Myers Squibb Co. -0.32% $144.49B
    Novartis AG ADR 0.20% $194.93B
    Abbott Laboratories -0.44% $209.94B
    Amgen Inc. -0.22% $143.27B
    GlaxoSmithKline PLC ADR -0.34% $93.07B
    Merck & Co. Inc. -0.73% $196.61B
    Competitor Data Provided ByCapital Cube Logo